Key result
Higher serum non-HDL-C is linked to ~36% higher odds of cognitive dysfunction after acute ischemic stroke.
Why the study?
The association between serum non-HDL-C and the risk of cognitive dysfunction in patients with AIS needed to be explored.
Cross-Sectional (n=583)
Assessor-blinded
No
Answers are grounded in this paper and cite their sources.
May warrant monitoring in acute stroke patients; leaves open causality and whether lowering non-HDL-C improves cognition.
This study aimed to explore the association between serum non-high-density lipoprotein cholesterol (non-HDL-C) and cognitive dysfunction risk in patients with acute ischemic stroke (AIS). This cross-sectional study enrolled 583 AIS patients. Biochemical markers and lipid profile were collected after admission. AIS patients were classified into high group (non-HDL-C ≥3.4 mM) and normal group (non-HDL-C <3.4 mM). Mini-Mental State Examination scale (MMSE), Montreal Cognitive Assessment scale (MoCA), Activities of Daily Living (ADL) scale, Neuropsychiatric Inventory (NPI), and Hamilton Depression scale 21 version (HAMD-21) were applied on the third day after admission. Compared with the control group, patients of the high group had higher body mass index and higher frequency of intracranial artery stenosis, and exhibited higher levels of non-HDL-C, total cholesterol, triglycerides, low-density lipoprotein cholesterol, homocysteine, fasting blood glucose, and glycosylated hemoglobin (HbA1c), and lower levels of high-density lipoprotein cholesterol (all P<0.05). Compared with the control group, patients of the high group had significantly lower MMSE and MoCA scores (MMSE: 26.01±4.17 vs 23.12±4.73, P<0.001; MoCA: 22.28±5.28 vs 20.25±5.87, P<0.001) and higher scores on the NPI and HAMD-21 (both P<0.001). MMSE (r=-0.306, P<0.001) and MoCA scores (r=-0.251, P<0.001) were negatively associated with non-HDL-C level. Multivariate regression analysis revealed that non-HDL-C level (OR=1.361, 95%CI: 1.059-1.729, P=0.016) was independently associated with the presence of cognitive dysfunction after adjusting for confounding factors. High serum non-HDL-C level might significantly increase the risk of cognitive dysfunction after AIS.
No takes yet. Share an insight, caveat, or question.
Jiao et al. (2020) conducted a cross-sectional in Acute ischemic stroke (n=583). High serum non-high-density lipoprotein cholesterol (non-HDL-C ≥3.4 mM) vs. Normal serum non-HDL-C (<3.4 mM) was evaluated on Cognitive dysfunction after acute ischemic stroke (assessed via MMSE and MoCA on day 3 after admission) (OR 1.361, 95% CI 1.059-1.729, p=0.016). Serum non-HDL-C was independently associated with cognitive dysfunction after acute ischemic stroke, with lower MMSE and MoCA scores in the high group.
Synapse has enriched 10 related papers. Consider them for comparative context: